Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTMQO60)

DTT Name Rho-associated protein kinase (ROCK)
Synonyms Rho-associated, coiled-coil-containing protein kinase; Rho associated protein kinase
Gene Name ROCK
DTT Type
Successful target
 [1]
UniProt ID
NOUNIPROTAC
TTD ID
T84726

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Netarsudil DM0LPI9 Open-angle glaucoma 9C61 Approved [2]
Ximelegatran DMU8ANS Myocardial infarction BA41-BA43 Approved [1]
------------------------------------------------------------------------------------
7 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Roclatan DMVQ5X1 Glaucoma/ocular hypertension 9C61 Phase 3 [3]
AMA-76 DMBWNX5 Glaucoma/ocular hypertension 9C61 Phase 2 [4]
AR-12286 DM5TC43 Glaucoma/ocular hypertension 9C61 Phase 2 [5]
Cethrin DMD3XMW Spinal cord injury ND51.2 Phase 1/2 [6]
Y-39983 DMXSEHF Glaucoma/ocular hypertension 9C61 Phase 1/2 [7]
AT13148 DMYIPKJ Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
STM 434 DMDF29A Ovarian cancer 2C73 Phase 1 [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Clinical Trial Drug(s)
8 Patented Agent(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hexahydro azepinone derivative 1 DMC1ZIX N. A. N. A. Patented [9]
Isoquinoline derivative 4 DMB5F8Q N. A. N. A. Patented [9]
Isoquinoline derivative 5 DMNJ2R9 N. A. N. A. Patented [9]
Isoquinoline sulfonamide derivative 1 DMM5BDS N. A. N. A. Patented [9]
Isoquinoline sulfonamide derivative 2 DMQVYL0 N. A. N. A. Patented [9]
Isoquinoline sulfonyl derivative 1 DMC5F3H N. A. N. A. Patented [9]
Isoquinoline sulfonyl derivative 2 DMT5E7M N. A. N. A. Patented [9]
Isoquinoline sulfonyl derivative 3 DMHIAVW N. A. N. A. Patented [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Patented Agent(s)

References

1 Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83.
2 Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4.
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014 Feb 18;55(2):1006-16.
5 Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011 Nov;152(5):834-41.e1.
6 A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma. 2011 May;28(5):787-96.
7 Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats.Curr Eye Res. 2011 Oct;36(10):964-70.
8 Company report (Astex)
9 Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515.